Deregulation of mTOR signaling is involved in thymic lymphoma development in Atm-/- mice

Biochemical and Biophysical Research Communications

Volumn 383, Issue 3, 2009, Pages 368-372

  Kuang, Xianghong ^a   Shen, Jianjun ^a   Wong, Paul K Y ^a   Yan, Mingshan ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

4EBP1; A T; ATM; c Myc; Cyclin D1; mTOR; Thymic lymphoma; Thymocyte

Indexed keywords

ATM PROTEIN; CYCLIN D1; MAMMALIAN TARGET OF RAPAMYCIN; MYC PROTEIN; RAPAMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; DEREGULATION; DISEASE COURSE; DNA SYNTHESIS; DOWN REGULATION; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; THYMOCYTE; THYMUS LYMPHOMA;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; CARRIER PROTEINS; CELL CYCLE PROTEINS; CYCLIN D1; DNA REPLICATION; DNA-BINDING PROTEINS; LYMPHOMA; MICE; MICE, KNOCKOUT; PHOSPHOPROTEINS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-MYC; SIGNAL TRANSDUCTION; SIROLIMUS; THYMUS NEOPLASMS; TUMOR SUPPRESSOR PROTEINS;

ANIMALIA; MAMMALIA; MUS;

EID: 67349195759     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.04.019     Document Type: Article

References (37)

1. Khanna K.K. Cancer risk and the ATM gene: a continuing debate. J. Nat. Cancer Inst. 92 (2000) 795-802
2. Goodarzi A.A., Jonnalagadda J.C., Douglas P., Young D., Ye R., Moorhead G.B., Lees-Miller S.P., and Khanna K.K. Autophosphorylation of ataxia-telangiectasia mutated is regulated by protein phosphatase 2A. EMBO J. 23 (2004) 4451-4461
3. Bakkenist C.J., and Kastan M.B. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 421 (2003) 499-506
4. Rotman G., and Shiloh Y. The ATM gene and protein: possible roles in genome surveillance, checkpoint controls and cellular defence against oxidative stress. Cancer Surv. 29 (1997) 285-304
5. Barlow C., Hirotsune S., Paylor R., Liyanage M., Eckhaus M., Collins F., Shiloh Y., Crawley J.N., Ried T., Tagle D., and Wynshaw-Boris A. Atm-deficient mice: a paradigm of ataxia telangiectasia. Cell 86 (1996) 159-171
6. Yan M., Qiang W., Liu N., Shen J., Lynn W.S., and Wong P.K. The ataxia-telangiectasia gene product may modulate DNA turnover and control cell fate by regulating cellular redox in lymphocytes. FASEB J. 15 (2001) 1132-1138
7. Zaldumbide A., Carlotti F., Pognonec P., and Boulukos K.E. The role of the Ets2 transcription factor in the proliferation, maturation, and survival of mouse thymocytes. J. Immunol. 169 (2002) 4873-4881
8. Cole M.D., and McMahon S.B. The Myc oncoprote: a critical evaluation of transactivation and target gene regulation. Oncogene 18 (1999) 2916-2924
9. Qi Y., Gregory M.A., Li Z., Brousal J.P., West K., and Hann S.R. p19ARF directly and differentially controls the functions of c-Myc independently of p53. Nature 431 (2004) 712-717
10. Davis A.C., Wims M., Spotts G.D., Hann S.R., and Bradley A. A null c-myc mutation causes lethality before 10.5 days of gestation in homozygotes and reduced fertility in heterozygous female mice. Genes Dev. 7 (1993) 671-682
11. Douglas N.C., Jacobs H., Bothwell A.L., and Hayday A.C. Defining the specific physiological requirements for c-Myc in T cell development. Nat. Immunol. 2 (2001) 307-315
12. Yan M., Zhu C., Liu N., Jiang Y., Scofield V.L., Riggs P.K., Qiang W., Lynn W.S., and Wong P.K. ATM controls c-Myc and DNA synthesis during postnatal thymocyte development through regulation of redox state. Free Radic. Biol. Med. 41 (2006) 640-648
13. Yan M., Kuang X., Scofield V.L., Shen J., Lynn W.S., and Wong P.K. The glucocorticoid receptor is increased in Atm-/- thymocytes and in Atm-/- thymic lymphoma cells, and its nuclear translocation counteracts c-myc expression. Steroids 72 (2007) 415-421
14. Yan M., Kuang X., Qiang W., Shen J., Claypool K., Lynn W.S., and Wong P.K. Prevention of thymic lymphoma development in Atm-/- mice by dexamethasone. Cancer Res. 62 (2002) 5153-5157
15. Hay N., and Sonenberg N. Upstream and downstream of mTOR. Genes Dev. 18 (2004) 1926-1945
16. Guertin D.A., and Sabatini D.M. An expanding role for mTOR in cancer. Trends Mol. Med. 11 (2005) 353-361
17. Brown E.J., Beal P.A., Keith C.T., Chen J., Shin T.B., and Schreiber S.L. Control of p70 s6 kinase by kinase activity of FRAP in vivo. Nature 377 (1995) 441-446
18. Graff J.R., Konicek B.W., Carter J.H., and Marcusson E.G. Targeting the eukaryotic translation initiation factor 4E for cancer therapy. Cancer Res. 68 (2008) 631-634
19. Kurmasheva R.T., Huang S., and Houghton P.J. Predicted mechanisms of resistance to mTOR inhibitors. Br. J. Cancer 95 (2006) 955-960
20. Gingras A.C., Kennedy S.G., O'Leary M.A., Sonenberg N., and Hay N. 4E-BP1, a repressor of mRNA translation, is phosphorylated and inactivated by the Akt(PKB) signaling pathway. Genes Dev. 12 (1998) 502-513
21. Rowinsky E.K. Targeting the molecular target of rapamycin (mTOR). Curr. Opin. Oncol. 16 (2004) 564-575
22. Sarbassov D.D., Ali S.M., Sengupta S., Sheen J.H., Hsu P.P., Bagley A.F., Markhard A.L., and Sabatini D.M. Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol. Cell 22 (2006) 159-168
23. Manning B.D., Tee A.R., Logsdon M.N., Blenis J., and Cantley L.C. Identification of the tuberous sclerosis complex-2 tumor suppressor gene product tuberin as a target of the phosphoinositide 3-kinase/akt pathway. Mol. Cell 10 (2002) 151-162
24. Potter C.J., Pedraza L.G., and Xu T. Akt regulates growth by directly phosphorylating Tsc2. Nat. Cell Biol. 4 (2002) 658-665
25. Inoki K., Li Y., Zhu T., Wu J., and Guan K.L. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat. Cell Biol. 4 (2002) 648-657
26. Zhang Y., Gao X., Saucedo L.J., Ru B., Edgar B.A., and Pan D. Rheb is a direct target of the tuberous sclerosis tumour suppressor proteins. Nat. Cell Biol. 5 (2003) 578-581
27. Garami A., Zwartkruis F.J., Nobukuni T., Joaquin M., Roccio M., Stocker H., Kozma S.C., Hafen E., Bos J.L., and Thomas G. Insulin activation of Rheb, a mediator of mTOR/S6K/4E-BP signaling, is inhibited by TSC1 and 2. Mol. Cell 11 (2003) 1457-1466
28. Inoki K., Li Y., Xu T., and Guan K.L. Rheb GTPase is a direct target of TSC2 GAP activity and regulates mTOR signaling. Genes Dev. 17 (2003) 1829-1834
29. Liao M.J., Yin C., Barlow C., Wynshaw-Boris A., and van Dyke T. Atm is dispensable for p53 apoptosis and tumor suppression triggered by cell cycle dysfunction. Mol. Cell Biol. 19 (1999) 3095-3102
30. Saha K., and Wong P.K. Rudimentary thymus of SCID mouse plays an important role in the development of retrovirus-induced neurologic disorders. Virology 195 (1993) 211-218
31. Mavrakis K.J., and Wendel H.G. Translational control and cancer therapy. Cell Cycle 7 (2008) 2791-2794
32. 2+ entry and NFAT activation in lymphocytes. Cell Calcium 42 (2007) 145-156
33. Wullschleger S., Loewith R., and Hall M.N. TOR signaling in growth and metabolism. Cell 124 (2006) 471-484
34. Matsuoka S., Ballif B.A., Smogorzewska A., McDonald III E.R., Hurov K.E., Luo J., Bakalarski C.E., Zhao Z., Solimini N., Lerenthal Y., Shiloh Y., Gygi S.P., and Elledge S.J. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316 (2007) 1160-1166
35. Park K.K., Liu K., Hu Y., Smith P.D., Wang C., Cai B., Xu B., Connolly L., Kramvis I., Sahin M., and He Z. Promoting axon regeneration in the adult CNS by modulation of the PTEN/mTOR pathway. Science 322 (2008) 963-966
36. Kim W.Y., and Snider W.D. Neuroscience. Overcoming inhibitions. Science 322 (2008) 869-872
37. Patursky-Polischuk I., Stolovich-Rain M., Hausner-Hanochi M., Kasir J., Cybulski N., Avruch J., Ruegg M.A., Hall M.N., and Meyuhas O. The TSC-mTOR pathway mediates translational activation of TOP mRNAs by insulin largely in a raptor- or rictor-independent manner. Mol. Cell Biol. 29 (2009) 640-649